Medical Editor: John P. Cunha, DO, FACOEP
Feridex I.V. (ferumoxides injectable solution) is a colloid of superparamagnetic iron oxide associated with dextran used for I.V. administration as an adjunct to MRI (in adult patients) to enhance the T2 weighted images used in the detection and evaluation of lesions of the liver that are associated with an alteration in the RES. The brand name Feridex I.V. is discontinued, but generic versions may be available. Common side effects of Feridex I.V. (ferumoxides injectable solution) include:
- back pain
- widening of blood vessels (vasodilation)
- leg pain
- chest pain
- shortness of breath
- weight loss
- abdominal pain
- neck pain
- high or low blood pressure
- irregular heartbeat
- numbness or tingling
- vision problems
- changes in taste
- nosebleed, or
- runny nose
The recommended dosage of Feridex I.V. is 0.56 milligrams of iron per kilogram of body weight, that is diluted in 100 mL of 5% dextrose solution and given over 30 minutes. Feridex I.V. may interact with iron supplements. Tell your doctor all medications and supplements you use. During pregnancy, Feridex I.V. should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Feridex I.V. (ferumoxides injectable solution) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In clinical trials, a total of 2240 subjects (32 healthy volunteers and 2208 patients with known or suspected liver lesions) received Feridex I.V. Of these subjects, 35% received the recommended dose of 0.56 mg Fe/kg and 62% received a dose of 0.84 mg Fe/kg. Forty-four percent were female and 56% were male, with a mean age of 54.9 years (range 11–89).
Of 866 subjects in whom race is known, 647 (75%) were Asian, 199 (22%) were Caucasian, 14 (2%) were Black, 3 ( < 1%) were Hispanic, and 3 ( < 1%) other. Racial demographic information was not available for the 1374 subjects in European clinical trials.
Of the 2240 subjects, 197 (8.8%) experienced an adverse event. The most commonly noted adverse experiences were back pain (3.4%), and vasodilation (2.3%).
In a subgroup of 1535 patients in controlled clinical trials, in 44 (2.9%) of the patients [9/226 (3.9%) in US, 10/635 (1.6%) in Japanese, and 25/674 (3.7%) in European studies] the infusion was interrupted or discontinued because of acute, moderate to severe pain (back, lower torso, chest, groin, or upper leg) with or without hypotension. Some patients required treatment. In a few of the patients with pain 11/44 (25%), the infusion was interrupted, restarted, and completed. (See WARNINGS section.)
Pain in any location was reported in 4.2% of these 1535 patients given Feridex I.V. (ferumoxides injectable solution)
In a subgroup of 689 patients in whom associated underlying disorders were evaluated, back pain occurred in 18/144 (12.5%) patients with cirrhosis and in 10/545 (1.8%) patients who did not have cirrhosis. The frequency of pain in patients with other liver abnormalities is not known.
Anaphylactic and allergic adverse events (e.g., generalized urticaria, respiratory symptoms, and hypotension) that required acute treatment occurred in 11/2240 (0.5%) of patients who received Feridex I.V. (ferumoxides injectable solution)
Most other adverse reactions were mild to moderate, of short duration, and resolved spontaneously without treatment. A relationship between adverse events and dose, age, or gender was not observed.
Adverse reactions that occurred in greater than or equal to 0.5% of the 1535 patients in controlled clinical trials are listed below in related categories, in decreasing order of occurrence within each system, and regardless of causality:
ADVERSE EVENTS IN ≥ 0.5% OF THE 1535 PATIENTS IN CONTROLLED
CLINICAL TRIALS WITH FERIDEX I.V. (ferumoxides injectable solution)
|Categories||Adverse Event||Number of Patients (%)|
|Number of patients who received Feridex I.V.||1535|
|Number of patients with any adverse event||144 (9.4%)|
|Digestive System||Nausea||11 (0.7%)|
|Body as a whole||Total (pain all sources)||65 (4.2%)|
|Pain Back/Leg/Pain Leg||56 (3.6%)|
|Pain Chest||10 (0.7%)|
|Hypersensitivity||Total (hypersensitivity all sources)||53 (3.4%)|
|Urticaria/Erythematous Rash/Rash||12 (0.7%)|
The following adverse reactions were observed in < 0.5% of the subjects receiving Feridex I.V. (ferumoxides injectable solution) : DIGESTIVE: diarrhea, vomiting, anorexia; BODY PAIN: pain abdomen, pain neck, fatigue, fever; CARDIOVASCULAR: hypertension, hypotension, arrhythmias; NERVOUS: dizziness, paresthesia; SKIN AND APPENDAGES: pruritus, sweating; SPECIAL SENSES: abnormal vision, taste perversion; RESPIRATORY: cough, epistaxis, rhinitis. (See sections on CONTRAINDICATIONS, WARNINGS and PRECAUTIONS.)
In 705 patients who received Feridex I.V. (ferumoxides injectable solution) in other trials, similar adverse events were reported.
Read the entire FDA prescribing information for Feridex IV (Ferumoxides Injectable Solution)